Incyte (INCY)
(Delayed Data from NSDQ)
$67.49 USD
+0.45 (0.67%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $67.64 +0.15 (0.22%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
INCY 67.49 +0.45(0.67%)
Will INCY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
Other News for INCY
Assessing Incyte: Insights From 11 Financial Analysts
Wolfe Research starts Incyte at Outperform amid 'major push' in I&I
Incyte initiated with bullish view at Wolfe Research
Multiple Late-Breaking Data Presentations from Incyte?s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase